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BACKGROUND:	 An	 inverse	 relationship	 between	 allergies	 with	 glioma	 risk	 has	 been	78 
reported	 in	 several	 but	 not	 all	 epidemiological	 observational	 studies.	 We	 performed	 an	79 
analysis	of	genetic	variants	associated	with	atopy	to	assess	the	relationship	with	glioma	risk	80 





hay	fever,	 IgE	 levels	and	self-reported	allergy	as	 instrumental	variables.	We	calculated	MR	86 
estimates	for	the	odds	ratio	(OR)	for	each	risk	factor	with	glioma	using	SNP-glioma	estimates	87 
from	12,488	 cases	 and	18,169	 controls,	 using	 inverse-variance	weighted	 (IVW),	maximum	88 
likelihood	 estimation	 (MLE),	weighted	median	 estimate	 (WME)	 and	mode-based	 estimate	89 




asthma	and	hay	fever,	self-reported	allergy	and	IgE	 levels	were	non-significant.	An	 inverse	94 





































few	 aetiological	 risk	 factors	 are	 well	 established	 for	 the	 disease	 [2].	 Over	 the	 past	 three	128 
decades	the	search	for	an	immune-mediated	risk	factor	that	might	influence	risk	has	led	to	129 




against	 glioma	 [4].	 For	 example,	 in	 the	 International	Adult	 Brain	 Tumour	 Study,	 based	on	134 
1,178	glioma	patients,	an	odds	ratio	(OR)	of	0.59	was	found	for	any	self-reported	allergy	[5].	135 
Other	case-control	studies	have	reported	similar	ORs,	however	most	have	been	reliant	on	136 
substantial	 numbers	 of	 proxy	 informants	 (up	 to	 44%)	 [4,	 6],	 and	 potential	 bias	 as	 a	137 
consequence	 of	 how	 controls	 were	 ascertained,	 thereby	 casting	 doubt	 on	 findings.	 In	138 




Assaying	 IgE	 potentially	 reduces	 bias	 stemming	 from	 self-reporting	 despite	 levels	 not	143 









case-control	 study	 nested	within	 the	 European	 Prospective	 Investigation	 into	 Cancer	 and	151 





disease	 and	 glioma	 [12].	 The	 findings	 could	 reflect	 a	 true	 causal	 effect	 of	 the	heightened	157 
immune	 function	 reported	 for	 atopy	 on	 tumour	 development.	 Alternatively,	 the	158 
associations	 observed	 might	 be	 non-causal,	 arising	 as	 a	 consequence	 of	 methodological	159 
biases	 inherent	 in	the	study	design.	 Imprecisely	defined	exposures	such	as	allergic	disease	160 
are	 likely	 to	 have	 affected	 the	 validity	 of	 the	 findings	 of	 both	 case-control	 and	 cohort	161 
studies.	The	heterogeneous	description	of	allergy	in	studies	and	different	levels	of	detail	in	162 
self-reporting	 on	 individual	 allergies	 complicate	 interpretation	 of	 the	 results.	 Additional	163 
biases	 include	 possible	 selection	 bias	 in	 controls,	 recall	 bias	 from	 self-reported	 allergy	164 
assessment	 and	 reverse	 causation	 or	 confounding	 from	 unmeasured	 effects.	 Finally,	 the	165 
high	 frequency	 of	 exposure	 ascertainment	 by	 proxy	 for	 cases	 is	 also	 likely	 to	 have	166 
systematically	biased	findings.		167 
	168 
Mendelian	 randomization	 (MR)	 analysis	 can	 be	 used	 to	 minimise	 potential	 biases	 in	169 
conventional	observational	studies	and	to	determine	the	causal	association	of	an	exposure	170 
with	an	outcome,	such	as	disease	risk	[13].	The	causal	association	can	also	be	manifested	by	171 
common	 genetic	 and	 biological	 pathways	 that	 determine	 two	 sequentially	 developed	172 
phenotypes,	such	as	an	atopic	trait	and	glioma	risk.	Atopy	has	a	strong	heritable	basis	[14,	173 






genetic	 scores	 summarising	 the	 effects	 of	 single	 nucleotide	 polymorphisms	 (SNPs)	178 




sample	MR	 [17]	 to	 estimate	 associations	 between	 atopy-associated	 SNPs	 and	 glioma	 risk	183 

























Glioma	 genotyping	 data	 were	 derived	 from	 the	 most	 recent	 meta-analysis	 of	 GWAS	 in	207 
glioma,	which	 related	 >10	million	 genetic	 variants	 (after	 imputation)	 to	 glioma,	 in	 12,488	208 
glioma	patients	and	18,169	controls	 from	eight	 independent	GWAS	datasets	of	 individuals	209 









SNPs	with	 the	strongest	effect	on	the	trait	 for	use	as	 IVs	 (Additional	 file	3:	Table	S2).	For	219 
each	 SNP,	we	 recovered	 the	 chromosome	position,	 risk	 allele,	 association	 estimates	 (per-220 
allele	 log-OR)	 and	 standard	 errors	 (SEs),	 summarised	 in	 Table	 1.	 The	 allele	 that	 was	221 
associated	with	increased	risk	of	the	exposure	was	considered	the	effect	allele.	For	IgE	level,	222 
the	allele	associated	with	an	 increase	 in	serum	 IgE	was	considered	the	effect	allele.	Allele	223 











The	 association	 between	 each	 atopy-related	 trait	 and	 glioma	was	 examined	 using	MR	on	233 




β =  !!!!!!!!!! !!!!!!!!!    .	
	238 
Where	Xk	corresponds	to	the	association	of	SNP	k	(as	log	of	the	OR	per	risk	allele)	with	the	239 
atopy-related	trait	Y,	Yk	 is	 the	association	between	SNP	k	and	glioma	risk	 (as	 log	OR)	with	240 
standard	error	!!! .	 The	estimate	 for	 (β)	 represents	 the	 causal	 increase	 in	 the	 log	odds	of	241 
glioma	for	each	trait.	The	standard	error	of	the	combined	ratio	estimate	is	given	by:		242 
	243 




For	 the	 maximum	 likelihood	 estimate,	 a	 bivariate	 normal	 distribution	 for	 the	 genetic	245 




A	central	 tenet	 in	MR	 is	 the	absence	of	pleiotropy	 (i.e.	 a	 gene	 influencing	multiple	 traits)	250 








Atopic	 dermatitis,	 asthma	 and	 hay	 fever,	 and	 self-reported	 allergyand	 all	 of	 the	 disease	259 





For	 each	 statistical	 test	 we	 considered	 a	 global	 significance	 level	 of	 P <0.05	 as	 being	265 
satisfactory	to	derive	conclusions.	To	assess	the	robustness	of	our	conclusions,	we	 initially	266 





evidence	 for	 an	 association.	 All	 statistical	 analyses	 were	 undertaken	 using	 R	 software	270 












Through	 simulation	we	evaluated	 the	 suitability	 of	 using	 each	employed	MR	method	 in	 a	283 
two-sample	 setting	with	 binary-exposure	 and	 binary-outcome	 data.	 For	 i	 index	N	 genetic	284 
variants	 and	 j	 index	 individuals	 genetic	 variants	 gij	 were	 generated	 independently	 by	285 
sampling	 from	 a	 Binomial(2,pj)	 distribution	 with	 probability	 pj	 drawn	 from	 a	286 
Uniform(0.1,0.9)	distribution,	to	mimic	bi-allelic	SNPs	in	Hardy-Weinberg	equilibrium.	Let	wj	287 
correspond	 to	 the	per-allele	OR	 for	 the	exposure	disease,	 sampled	 from	ORs	 reported	 for	288 
genome-wide	significant	SNPs	reported	in	the	GWAS	Catalog	[37],	and	v	be	the	OR	for	the	289 
outcome	 disease	 per	 doubling	 in	 odds	 of	 the	 exposure	 disease.	 For	 each	 individual,	290 
exposure	disease	odds	xj,	outcome	disease	odds	yj,	exposure	disease	status	aj,	and	outcome	291 
disease	status	bj	were	determined	as	follows:		292 
!! = !! !!!!"!!!! 	
13	
	










outcome	diseases	were	 similar	 to	 that	 of	 the	 atopy-related	 traits	 and	 glioma	 respectively	302 
(Additional	file	6:	Table	S5).	To	determine	the	suitability	of	each	MR	method	we	considered	303 
two	scenarios:	(i)	no	causal	relationship	between	exposure	and	outcome	(v=1.00)	and	(ii)	a	304 













The	atopic	dermatitis	 risk	 SNP	 rs909341,	which	 is	highly	 correlated	with	 the	 chromosome	316 
20q13.33	glioma	risk	SNP	rs2297440	(D’=0.89,	r2=0.77),	was	strongly	associated	with	risk	of	317 
glioma	(P=2.10x10-34).	Testing	for	pleiotropy	using	HEIDI	outlier-analysis	formally	 identified	318 







0.377,	 0%	 and	 0.444,	 and	 0%	 and	 0.707).	 Including	 rs909341	 in	 the	 analysis	 for	 atopic	326 




Using	 the	 IVW	method	 to	 pool	 results	 from	 individual	 SNPs,	 no	 associations	 (i.e.	P≥0.05)	331 
were	identified	between	genetically	conferred	risk	of	raised	IgE	level	(OR=0.88,	95%	CI=0.69-332 
1.13,	 P=0.319),	 asthma	 and	 hay	 fever	 (OR=0.96,	 95%	 CI=0.90-1.03,	 P=0.248),	 or	 self-333 
reported	 allergy	 (OR=1.03,	 95%	 CI=0.95-1.11,	 P=0.534)	 with	 risk	 of	 all	 glioma.	 There	 was	334 
some	 support	 for	 an	 inverse	 relationship	 between	 atopic	 dermatitis	 and	 glioma	 risk	335 





Using	MLE,	no	associations	were	 identified	between	asthma	and	hay	 fever	 (OR=0.96,	95%	339 
CI=0.93-1.00,	 P=0.066),	 IgE	 levels	 (OR=0.88,	 95%	 CI=0.74-1.05,	 P=0.157)	 or	 self-reported	340 
allergy	 (OR=1.02,	95%	CI=0.97-1.08,	P=0.429)	with	risk	of	all	glioma.	For	atopic	dermatitis,	341 
an	 OR	 of	 0.96	 (95%	 CI=0.94-0.99,	 P=0.003)	 was	 shown,	 which	 remained	 significant	 after	342 
adjusting	 for	 multiple	 testing.	 Figure	 2	 shows	 relaxation	 of	 the	 assumption	 that	 the	343 










IgE,	 asthma	and	hay	 fever,	 and	 self-reported	allergy	were	0.97	 for	 atopic	dermatitis	 (95%	354 
CI=0.92-1.03;	P=0.375)	0.63	for	IgE	levels	(95%	CI=0.32-1.25;	P=0.184),	0.99	for	asthma	and	355 
hay	fever	(95%	CI=0.72-1.36,	P=0.951)	and	0.92	for	self-reported	allergy	(95%	CI=0.69-1.22;	356 
P=0.540),	with	 intercepts	of	 -0.004	 (95%	CI=-0.014-0.006,	P=0.396),	0.027	 (95%	CI=-0.001-357 
0.053,	 P=0.042),	 -0.007	 (95%	 CI=-0.030-0.016,	 P=0.542)	 and	 0.017	 (95%	 CI=0.003-0.031,	358 
P=0.018).	Collectively	these	findings	provide	possible	evidence	of	systematic	bias	in	the	IVW	359 







specific,	 considering	 GBM	 and	 non-GBM	 separately.	 Imposing	 a	 stronger	 significance	365 
threshold	 of	P=0.00625	 (0.05/8,	 to	 correct	 for	 testing	 four	 traits	 over	 two	 outcomes),	 no	366 
histology-specific	 associations	were	 shown	 by	 the	 IVW	method	 between	 asthma	 and	 hay	367 
fever,	 IgE	 levels	 and	 self-reported	 allergy	 and	 glioma	 risk,	 respective	 ORs	 for	 the	 IVW	368 
method	 being	 0.97,	 0.92,	 and	 1.04	 for	 GBM	 tumours,	 0.96,	 0.97,	 and	 1.04	 for	 non-GBM	369 
tumours	 (Additional	 file	 7:	 Table	 S6).	 For	 atopic	dermatitis,	 a	 significant	OR	of	 0.94	 (95%	370 
CI=0.90-0.98,	P=0.004)	was	shown	for	GBM	but	not	 for	non-GBM	(OR=0.98,	95%	CI=	0.93-371 







Although	previously	 implemented	 in	other	 studies	 [32,	38],	 ratio	estimators	may	not	 fully	379 
recapitulate	 an	 estimate	 of	 the	 causal	 OR	 in	 the	 case	 of	 binary-exposures	 such	 as	 atopic	380 
dermatitis,	 and	 binary-outcomes	 such	 as	 glioma	 [39].	 We	 therefore	 evaluated	 through	381 













atopic	 dermatitis	 with	 GBM	 tumours,	 but	 do	 not	 provide	 evidence	 that	 asthma	 and	 hay	393 
fever,	 raised	 IgE	 levels,	or	 self-reported	allergy	 is	protective	against	 the	 risk	of	developing	394 
glioma.		395 
	396 






A	key	assumption	 in	MR	 is	 that	 the	 instrument	 affects	 glioma	 risk	 through	 its	 effect	on	a	403 
specific	phenotype/exposure	(i.e.	atopic	traits),	and	does	not	have	a	direct	effect	on	glioma	404 
risk.	We	 tested	 this	 assumption	using	MR-Egger	 regression	 and	HEIDI	 outlier	 analysis	 and	405 
found	possible	evidence	of	violation	of	this	assumption	for	IgE	and	self-reported	allergy.	It	is	406 
notable	 that	 self-reported	 allergy	 does	 not	 show	 an	 approximately	 quadratic	 response	 to	407 
correlation,	 in	 contrast	 to	 asthma	 and	 hay	 fever,	 atopic	 dermatitis,	 and	 IgE	 level.	 This	 is	408 







strong	evidence	 for	an	 inverse	 relationship	between	atopy	and	glioma	risk	 [40].	However,	414 
most	 of	 the	 support	 for	 such	 a	 relationship	 comes	 from	 the	 case-control	 studies	 [4].	 A	415 
common	limitation	in	retrospective	studies	of	glioma	has	been	the	use	of	proxy	respondents	416 
for	 cases	 who	 have	 cognitive	 impairment.	 A	 related	 issue	 is	 that	 glioma	 cases	 may	 not	417 
remember	 past	 exposures	 accurately	 due	 to	 cognitive	 deficits	 [4].	 Such	 issues	 are	418 
compounded	by	the	fact	that	across	studies	multiple	atopic	traits	have	been	assessed.	The	419 
strength	of	 support	 for	a	 relationship	 seen	across	 case-control	 studies	 contrasts	markedly	420 
with	the	limited	the	evidence	for	a	relationship	from	prospective	cohort-based	analyses	[7].			421 
	422 
By	 inference,	 a	 relationship	 between	 long-term	 antihistamine	 use	 could	 theoretically	423 
provide	 supporting	 evidence,	 albeit	 indirect,	 that	 atopic	 mediated	 mechanisms	 influence	424 
glioma	risk.	However,	the	impact	of	antihistamine	use	is	difficult	to	disentangle	from	that	of	425 
allergies,	 as	 these	 factors	 are	 highly	 correlated,	 and	 few	 individuals	without	 allergies	 use	426 
antihistamines	 regularly.	 Paradoxically	 an	 increased	 risk	 for	 glioma	 associated	 with	427 
antihistamine,	 particularly	 among	 individuals	 with	 allergic	 conditions,	 has	 been	 found	 in	428 
some	studies	[41,	42].		429 
	430 
Raised	 IgE	 levels	 and	 self-reported	 allergy	 suffer	 limitations	 as	 traits	 used	 to	 assess	 the	431 
effect	of	atopy	on	glioma	risk	as	they	are	both	variable	over	short	time	scales	in	their	level	432 
of	expression	 (in	 contrast	 to	 clinical	diagnosis	of	 atopic	dermatitis).	 Further,	 allergies	may	433 
develop	later	in	life,	and	patients	may	not	necessarily	exhibit	symptoms.	This	introduces	the	434 






glioma	risk	seen	 in	this	study	 is	 that	the	causality	 is	 in	 fact	reversed,	which	could	result	 in	439 
epidemiological	observational	 studies	 reporting	 inverse	 relationships	 [8,	9],	but	would	not	440 
affect	an	MR	analysis.	Immunosuppression	caused	by	glioblastoma	is	well	documented	[43,	441 







Egger	 methods	 have	 been	 demonstrated	 to	 accurately	 estimate	 causal	 effects	 using	449 
summary-level	 data	 [28,	 30,	 31,	 45].	 However,	 using	 summary-level	 data	 instead	 of	450 
individual-level	data	 limits	 the	approaches	 that	 can	be	used	 to	 test	 the	validity	of	genetic	451 
variants	 as	 IVs,	 as	 adjusting	 for	 measured	 covariates	 and	 assessing	 gene-environment	452 
interactions	 is	 generally	 not	 possible	 using	 summary-level	 data	 [46].	 The	 first-stage	 F	453 
statistic	was	large	(>25	for	all	traits),	and	so	weak	instrument	bias	is	unlikely.	454 
	455 
Epidemiological	 observational	 studies	have	 reported	 inverse	 relationships	between	atopy-456 
related	traits	and	glioma	risk,	with	ORs	in	the	range	0.43-0.96	for	asthma	[6,	47],	0.42-0.90	457 
for	atopic	dermatitis	 [6,	47],	0.37-0.73	 for	 IgE	 levels	 [8-10]	and	0.47-0.69	 for	self-reported	458 
allergies	[4,	5,	8].	Odds	ratios	for	binary	exposures	estimated	in	this	MR	study	represent	the	459 













Our	 study	 does	 however	 have	 limitations.	 Firstly,	 while	 it	 is	 entirely	 appropriate	 to	471 
implement	different	MR	methods	 to	assess	 the	 robustness	of	 finding,	 they	have	different	472 
differing	power	 to	demonstrate	associations,	with	 the	WME,	MBE	and	MR-Egger	methods	473 
having	 less	power	 than	 IVW	and	MLE.	 Irrespective	of	 such	 factors	our	study	had	only	had	474 
80%	 power	 to	 detect	 ORs	 of	 1.16,	 1.09,	 1.16	 and	 1.22	 for	 asthma	 and	 hay	 fever,	 atopic	475 
dermatitis,	IgE	level	and	self-reported	allergy	respectively	(Additional	file	5:	Table	S4).	This	476 




risk	 might	 be	 mediated	 through	 mechanisms	 associated	 with	 a	 trait	 that	 we	 have	 not	481 
captured	by	using	MR	to	assess	asthma	and	hay	fever,	and	self-reported	allergy.	Secondly,	a	482 
weakness	of	the	two-sample	MR	strategy	is	that	it	does	not	allow	examination	of	non-linear	483 
































































































Genotype	 data	 from	 the	 GICC	 GWAS	 are	 available	 from	 the	 database	 of	 Genotypes	 and	572 










from	 the	 National	 Institutes	 of	 Health,	 Bethesda,	Maryland	 (R01CA139020,	 R01CA52689,	583 
P50097257,	 P30CA125123).	 The	 UK	 Interphone	 Study	 was	 supported	 by	 the	 European	584 
Commission	 Fifth	 Framework	 Program	 “Quality	 of	 Life	 and	 Management	 of	 Living	585 







R.S.H.	 and	 A.J.C.	 managed	 the	 project.	 L.D-H.,	 A.J.C.,	 A.S.,	 P.J.L.	 and	 R.S.H.	 drafted	 the	591 
manuscript.	 L.D-H.	 and	 A.J.C.	 performed	 statistical	 analyses.	 B.K.,	 K.L.,	 M.J.S.	 and	 R.H.S.	592 
acquired	 and	 analysed	 the	 U.K.	 data.	 M.	 Simon,	 P.H.,	 M.M.N.	 and	 K.-H.J.	 acquired	 and	593 
analysed	 the	German	data.	D.I.J.,	Q.T.O.,	 J.E.E.-P.,	G.N.A.,	 E.B.C.,	D.I.,	 J.S.,	 J.S.B.-S.,	 S.H.O.,	594 
J.L.B.,	R.K.L.,	C.J.,	R.B.J.,	B.S.M.,	M.R.W.,	M.L.B.	and	R.S.H.	acquired	and	analysed	the	GICC	595 






















Region	 SNP	 Position	(bp)*	 Alleles**	 MAF	 Hay	Fever	and	Asthma	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
2q12.1	 rs10197862	 102966549	 G/A	 G=0.161	 1.24	(1.16-1.32)	 0.98	(0.93−1.03)	
4p14	 rs4833095	 38799710	 C/T	 T=0.425	 1.20	(1.14-1.26)	 1.03	(0.99−1.08)	
5q22.1	 rs1837253	 110401872	 T/C	 T=0.382	 1.17	(1.11-1.23)	 0.96	(0.93−1.00)	
8q21.13	 rs7009110	 81291879	 C/T	 C=0.467	 1.14	(1.09-1.19)	 0.98	(0.94−1.01)	
9p24.1	 rs72699186	 6175855	 A/T	 T=0.110	 1.26	(1.17-1.36)	 0.97	(0.93−1.02)	
11q13.5	 rs2155219	 76299194	 G/T	 G=0.468	 1.17	(1.13-1.21)	 1.01	(0.97−1.05)	
15q22.33	 rs17294280	 67468285	 A/G	 G=0.120	 1.18	(1.12-1.25)	 0.98	(0.94−1.03)	
16p13.13	 rs62026376	 11228712	 T/C	 T=0.144	 1.17	(1.11-1.23)	 0.97	(0.93−1.01)	
17q21.1	 rs7212938	 38122680	 T/G	 G=0.473	 1.16	(1.11-1.22)	 1.00	(0.97−1.04)	
	616 
Region	 SNP	 Position*	 Alleles**	 MAF	 Atopic	Dermatitis	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
1q21.3	 rs11205006	 152440176	 T/A	 A=0.265	 1.62	(1.48-1.77)	 0.96	(0.91−1.02)	
1q21.3	 rs2228145	 154426970	 A/C	 C=0.293	 1.15	(1.10-1.20)	 0.99	(0.96−1.03)	
2p25.1	 rs10199605	 8495097	 A/G	 A=0.244	 1.04	(1.03-1.06)	 1.01	(0.97−1.05)	
2p13.3	 rs112111458	 71100105	 G/A	 G=0.224	 1.08	(1.05-1.10)	 0.98	(0.92−1.03)	
2q24.3	 rs6720763	 167992286	 T/C	 C=0.320	 1.29	(1.18-1.41)	 1.02	(0.97−1.06)	
5p13.2	 rs10214237	 35883734	 C/T	 C=0.176	 1.06	(1.05-1.08)	 0.98	(0.94−1.02)	
5q31.1	 rs1295686	 131995843	 C/T	 T=0.422	 1.35	(1.22-1.49)	 0.99	(0.95−1.03)	
6p21.32	 rs12153855	 32074804	 T/C	 C=0.125	 1.58	(1.40-1.78)	 0.97	(0.92−1.03)	
8q21.13	 rs6473227	 81285892	 A/C	 A=0.473	 1.06	(1.05-1.08)	 0.98	(0.94−1.02)	
9p21.3	 rs10738626	 22373457	 C/T	 C=0.397	 1.23	(1.15-1.32)	 0.96	(0.93−1.00)	
10p15.1	 rs6602364	 6038853	 G/C	 G=0.492	 1.05	(1.03-1.07)	 1.03	(0.99−1.07)	
11q13.1	 rs10791824	 65559266	 A/G	 G=0.490	 1.15	(1.12-1.19)	 0.99	(0.95−1.02)	
11q24.3	 rs7127307	 128187383	 C/T	 C=0.488	 1.09	(1.07-1.11)	 0.99	(0.95−1.03)	
11q13.5	 rs7130588	 76270683	 G/A	 G=0.216	 1.29	(1.20-1.38)	 1.02	(0.98−1.06)	
14q13.2	 rs2143950	 35572357	 C/T	 T=0.215	 1.08	(1.06-1.10)	 1.01	(0.97−1.06)	
16p13.13	 rs2041733	 11229589	 C/T	 T=0.496	 1.09	(1.06-1.11)	 0.97	(0.94−1.01)	
19p13.2	 rs2164983	 8789381	 C/A	 A=0.169	 1.16	(1.10-1.22)	 0.95	(0.90−1.00)	
20q13.33	 rs909341	 62328742	 T/C	 T=0.262	 1.32	(1.21-1.44)	 1.32	(1.26−1.37)	
	617 
Region	 SNP	 Position*	 Alleles**	 MAF	 IgE	level***	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
1q23.2	 rs2251746	 159272060	 C/T	 C=0.015	 1.09	(1.08-1.11)	 0.98	(0.95−1.02)	
5q31.1	 rs20541	 131995964	 A/G	 A=0.270	 1.08	(1.06-1.10)	 1.01	(0.97−1.06)	
6p22.1	 rs2571391	 29923838	 C/A	 C=0.303	 1.06	(1.05-1.08)	 0.97	(0.94−1.01)	
6p21.32	 rs2858331	 32681277	 A/G	 G=0.490	 1.04	(1.03-1.06)	 1.02	(0.98−1.06)	
12q13.3	 rs1059513	 57489709	 C/T	 C=0.070	 1.13	(1.09-1.17)	 0.97	(0.92−1.03)	
	618 
Region	 SNP	 Position*	 Alleles**	 MAF	 Self-reported	allergy	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
2q12.1	 rs10189699	 102879464	 A/C	 A=0.143	 1.16	(1.12-1.20)	 0.99	(0.94−1.04)	
2q33.1	 rs10497813	 198914072	 T/G	 T=0.401	 1.08	(1.05-1.11)	 0.99	(0.96−1.03)	
3q28	 rs9860547	 188128979	 G/A	 A=0.272	 1.08	(1.05-1.11)	 1.02	(0.98−1.06)	
4p14	 rs2101521	 38811551	 A/G	 A=0.475	 1.15	(1.12-1.18)	 1.02	(0.98−1.07)	
4q27	 rs17388568	 123329369	 G/A	 A=0.141	 1.08	(1.05-1.11)	 1.01	(0.97−1.05)	
5p13.1	 rs7720838	 40486896	 G/T	 T=0.362	 1.08	(1.06-1.11)	 1.02	(0.99−1.06)	
5q22.1	 rs1438673	 110467499	 T/C	 C=0.296	 1.12	(1.09-1.15)	 0.97	(0.94−1.01)	
6p21.33	 rs9266772	 31352113	 T/C	 C=0.175	 1.11	(1.08-1.14)	 1.03	(0.98−1.08)	
9p24.1	 rs7032572	 6172380	 A/G	 G=0.114	 1.12	(1.08-1.16)	 0.97	(0.93−1.02)	
10p14	 rs962993	 9053132	 T/C	 T=0.106	 1.07	(1.05-1.10)	 1.02	(0.98−1.06)	
11q13.5	 rs2155219	 76999194	 G/T	 G=0.468	 1.11	(1.09-1.14)	 1.01	(0.97−1.05)	
15q22.33	 rs17228058	 67450305	 A/G	 G=0.100	 1.08	(1.05-1.11)	 1.00	(0.96−1.04)	
17q21.1	 rs9303280	 38074031	 T/C	 T=0.346	 1.07	(1.05-1.09)	 0.98	(0.94−1.02)	





Table	 2:	 IVW,	 MLE,	 WME,	 MBE	 and	 MR-Egger	 test	 results	 for	 combined	 atopy-related	621 
instrumental	variables	622 
	623 
Trait	 IVW	 MLE	 WME	 MBE	 MR-Egger	slope	 MR-Egger	intercept	
OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
OR	(95%	CI)	 P	




0.96	(0.90-1.03)	 0.248	 0.96	(0.93-1.00)	 0.066	 0.93	(0.86-1.01)	 0.087	 0.91	(0.80-1.04)	 0.191	 0.99	(0.72-1.36)	 0.951	 -0.007	(-0.030-0.016)	 0.542	
Atopic	
dermatitis	
0.96	(0.93-1.00)	 0.041	 0.96	(0.94-0.99)	 0.003	 0.96	(0.91-1.01)	 0.114	 0.97	(0.92-1.02)	 0.194	 0.97	(0.92-1.03)	 0.375	 0.004	(-0.014-0.006)	 0.396	




1.03	(0.95-1.11)	 0.534	 1.02	(0.97-1.08)	 0.429	 1.08	(0.97-1.20)	 0.184	 1.12	(0.92-1.36)	 0.275	 0.92	(0.69-1.22)	 0.540	 0.017	(0.003-0.031)	 0.018	
	624 

















Figure	 1:	 Forest	 plot	 of	 Wald	 ORs	 and	 95%	 confidence	 intervals	 generated	 from	 SNPs	640 
associated	 with	 atopy-related	 traits.	 ORs	 for	 individual	 SNPs	 are	 listed	 according	 to	641 

































































































































Figure	 2:	 Plot	 of	 P	 value	 of	 MLE	 associations	 with	 glioma	 against	 correlation	 between	648 







































Figure	 3:	 Scatter	 plots	 of	 genetic	 associations	 with	 glioma	 against	 genetic	 associations	652 








0.00 0.05 0.10 0.15 0.20



















































































































































































































































































































































hay	fever Chr 2 4 5 5 8 9 11 15 16
Chr rsid rs10197862 rs4833095 rs1438673 rs1837253 rs7009110 rs72699186 rs2155219 rs17294280 rs62026376
2 rs10197862 1
4 rs4833095 0 1
5 rs1438673 0 0 1
5 rs1837253 0 0 0.0290264 1
8 rs7009110 0 0 0 0 1
9 rs72699186 0 0 0 0 0 1
11 rs2155219 0 0 0 0 0 0 1
15 rs17294280 0 0 0 0 0 0 0 1
16 rs62026376 0 0 0 0 0 0 0 0 1
17 rs7212938 0 0 0 0 0 0 0 0 0
Atopic	
Dermatitis Chr 1 1 1 1 1 1 2 2 2
Chr rsid rs11205006 rs12144049 rs2228145 rs61813875 rs6661961 rs7512552 rs10199605 rs112111458rs6419573
1 rs11205006 1
1 rs12144049 1 1
1 rs2228145 0.00033237 9.48E-05 1
1 rs61813875 0.0346025 0.0746275 2.95E-05 1
1 rs6661961 0.477915 0.5082 0.00028748 0.0345781 1
1 rs7512552 0.002187 0.00051363 1.61E-05 0.00016209 0.00036636 1
2 rs10199605 0 0 0 0 0 0 1
2 rs112111458 0 0 0 0 0 0 0.00011906 1
2 rs6419573 0 0 0 0 0 0 2.76E-05 0.0033077 1
2 rs6720763 0 0 0 0 0 0 0.00011986 6.94E-05 0.00242265
5 rs10214237 0 0 0 0 0 0 0 0 0
5 rs12188917 0 0 0 0 0 0 0 0 0
5 rs1295686 0 0 0 0 0 0 0 0 0
5 rs2897442 0 0 0 0 0 0 0 0 0
5 rs4705962 0 0 0 0 0 0 0 0 0
6 rs12153855 0 0 0 0 0 0 0 0 0
6 rs41268896 0 0 0 0 0 0 0 0 0
6 rs4713555 0 0 0 0 0 0 0 0 0
8 rs6473227 0 0 0 0 0 0 0 0 0
9 rs10738626 0 0 0 0 0 0 0 0 0
10 rs6602364 0 0 0 0 0 0 0 0 0
11 rs10791824 0 0 0 0 0 0 0 0 0
11 rs2212434 0 0 0 0 0 0 0 0 0
11 rs479844 0 0 0 0 0 0 0 0 0
11 rs7127307 0 0 0 0 0 0 0 0 0
11 rs7130588 0 0 0 0 0 0 0 0 0
11 rs7927894 0 0 0 0 0 0 0 0 0
14 rs2143950 0 0 0 0 0 0 0 0 0
16 rs2041733 0 0 0 0 0 0 0 0 0
19 rs2164983 0 0 0 0 0 0 0 0 0
19 rs2918307 0 0 0 0 0 0 0 0 0
20 rs4809219 0 0 0 0 0 0 0 0 0
20 rs6010620 0 0 0 0 0 0 0 0 0
20 rs909341 0 0 0 0 0 0 0 0 0
IgE	levels Chr 1 1 1 5 6 6 6 12
Chr rsid rs4656784 rs13962 rs2251746 rs20541 rs2858331 rs2571391 rs2523809 rs1059513
1 rs4656784 1
1 rs13962 0.3643 1
1 rs2251746 0.462008 0.410714 1
5 rs20541 0 0 0 1
6 rs2858331 0 0 0 0 1
6 rs2571391 0 0 0 0 0.00010884 1
6 rs2523809 0 0 0 0 0.0130407 0.0648709 1
12 rs1059513 0 0 0 0 0 0 0 1
Self-
reported	
allergy Chr 2 4 5 5 8 9 11 15 16
Chr rsid rs10197862 rs4833095 rs1438673 rs1837253 rs7009110 rs72699186 rs2155219 rs17294280 rs62026376
2 rs10197862 1
4 rs4833095 0 1
5 rs1438673 0 0 1
5 rs1837253 0 0 0.0290264 1
8 rs7009110 0 0 0 0 1
9 rs72699186 0 0 0 0 0 1
11 rs2155219 0 0 0 0 0 0 1
15 rs17294280 0 0 0 0 0 0 0 1
16 rs62026376 0 0 0 0 0 0 0 0 1




2 5 5 5 5 5 6 6 6 8 9




0 5.00E-06 0.24802 1
0 0.0002101 0.0239946 0.162452 1
0 0.00047095 0.0348378 0.180208 0.858099 1
0 0 0 0 0 0 1
0 0 0 0 0 0 0.0452232 1
0 0 0 0 0 0 0.18826 0.0275876 1
0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0




10 11 11 11 11 11 11 14 16 19 19




0 0.938237 0.00055208 1
0 0.00037286 0.00059044 0.00025972 1
0 0.00024611 0.674246 0.00036951 0.00047794 1
0 0.00028194 0.597991 0.00067521 0.00095006 0.84696 1
0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 1 1
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0



















Asthma	and	hay	fever 0.86-1.16 0.82-1.22 0.82-1.22
Atopic	dermatitis 0.92-1.09 0.89-1.11 0.89-1.11
IgE	levels 0.86-1.16 0.83-1.21 0.83-1.21





Asthma	and	hay	fever i 1.00 9 6,685 14,091 12,488 18,169 0.010
Atopic	dermatitis i 1.00 18 21,399 95,464 12,488 18,169 0.092
Self-reported	allergy i 1.00 14 26,311 27,551 12,488 18,169 0.044
Asthma	and	hay	fever ii 1.33 9 6,685 14,091 12,488 18,169 0.015
Atopic	dermatitis ii 1.33 18 21,399 95,464 12,488 18,169 0.110






























Outcome IVW MLE WME MBE MR-Egger
0.010 0.999	(0.015) 0.999	(0.014) 0.998	(0.018) 0.998	(0.019) 0.999	(0.027)
0.010 1.002	(0.010) 1.002	(0.009) 1.002	(0.012) 1.001	(0.014) 1.003	(0.018)
0.010 1.000	(0.014) 1.001	(0.012) 0.999	(0.015) 0.999	(0.015) 0.996	(0.023)
0.001 1.327	(0.022) 1.329	(0.025) 1.326	(0.027) 1.327	(0.026) 1.324	(0.046)
0.004 1.359	(0.029) 1.355	(0.031) 1.356	(0.029) 1.357	(0.029) 1.356	(0.030)





Trait OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI)
Asthma	and	hay	fever 0.97	(0.89-1.06) 0.515 0.98	(0.93-1.03) 0.375 0.95	(0.86-1.05) 0.349 0.92	(0.75-1.12) 0.429 1.01	(0.68-1.49)
Atopic	dermatitis 0.94	(0.90-0.98) 0.004 0.94	(0.91-0.97) 2.17E-04 0.96	(0.91-1.02) 0.172 0.95	(0.90-1.01) 0.096 0.96	(0.89-1.03)
IgE	levels 0.92	(0.67-1.25) 0.587 0.92	(0.74-1.14) 0.427 0.78	(0.54-1.13) 0.191 0.77	(0.50-1.18) 0.300 0.46	(0.20-1.06)
Self-reported	allergy 1.04	(0.94-1.15) 0.473 1.04	(0.96-1.11) 0.327 1.05	(0.92-1.20) 0.463 1.06	(0.88-1.27) 0.566 0.94	(0.66-1.33)
IVW:	inverse	variance	weighted;	MLE:	maximum	likelihood	estimate;	WME:	weighted	median	estimate,	MBE:	mode-based	estimate
IVW MLE MBE MR-Egger
GBM
WME
P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value
0.985 0.96	(0.90-1.04) 0.325 0.96	(0.91-1.02) 0.161 0.95	(0.86-1.05) 0.343 0.92	(0.79-1.07) 0.313 0.91	(0.60-1.39) 0.656
0.237 0.98	(0.93-1.03) 0.421 0.99	(0.96-1.03) 0.602 0.96	(0.90-1.03) 0.267 0.96	(0.90-1.02) 0.236 0.96	(0.89-1.04) 0.320
0.067 0.97	(0.70-1.35) 0.853 0.97	(0.77-1.22) 0.791 1.09	(0.74-1.62) 0.651 1.11	(0.71-1.72) 0.670 1.21	(0.59-2.94) 0.668
0.718 1.04	(0.94-1.15) 0.473 1.04	(0.96-1.11) 0.327 1.05	(0.92-1.20) 0.446 1.06	(0.86-1.29) 0.601 0.77	(0.53-1.13) 0.178
MR-Egger
GBM Non-GBM	glioma
IVW MLE MBE MR-EggerWME
